

TABLE OF CONTENTS

February 16, 2009

No. 2127

BUSINESS

- 1 Eli Lilly Japan to Conduct More PI Clinical Trials in Japan
- 2 Chugai to Apply for 5 Products in 2009
 - Sales Down 5.2% Despite Strong Growth of Anticancer Drugs
 - Chugai Leads Oncology Market in Japan
- 3 Price Settlement Rate Up to 81.6% in December
 - New Invoice Prices Needed to Eliminate Wholesalers' Losses on Sales
- 4 **BUSINESS NEWS IN BRIEF**
 - Shionogi Licenses Therapeutic Vaccines for Cancer from OTS
 - GSK to Tie Up with Kaketsuken to Manufacture Pandemic Vaccines
 - Urief Capsule to Be Replaced with Tablet
 - AnGes MG Partly Terminates Agreement on HGF Drug with Daiichi Sankyo
 - GenomIdea Licenses HVJ Envelope to TSD Japan
- 5 **ON THE MOVE**
 - Denroku Ishiguro to Serve as President of Alfresa HD
- 6 **3-Qtr Business Results: 2**
 - Ono: Generics, NHI Price Cuts Hit Business
 - Santen: Transient Slowdown of Market Growth Hits Business
 - Kyorin: Kipres, Pentasa Prop Up Sales
 - Kaken: Sales, Profits Up Driven by Artz
 - Mochida: Strong Growth in Sales of Atelec Supports Business
 - Kissei: New Products Prop Up Profits
 - Fuso: Medical Device Lixelle Drives Business Back to the Black
 - Torii: Sales Down 9.7% due to Transfer of Minophagen Products
 - Seikagaku: Sales Down 4.4% Despite Expansion of Market for Artz
 - Tsumura: Sales Up for 106 of 129 Kampo Formulations
 - Nippon Chemiphar: Generics Drive Sales, but Profits Plummet
 - Wakamoto: Sales of New Products Disappointing
 - Asahi Kasei Pharma: License Fee for Famvir Buttresses Business
 - Yakult: Elplat Drives Pharma Sales by 10.8%
 - Mediceo Paltac: Sales Up 9.2%, Profits Down Sharply
 - Alfresa: Sharp Drop in Profits Despite Strong Growth in Sales
 - Suzuken: Sharp Fall in Profits with 2.8% Growth in Sales
 - Toho Pharm.: Net Loss due to Bankruptcy of Fuji Biomedix

SPONSOR FEATURE

- 10 Japan's Most Admired Pharma Companies in 2008: P. Reed Maurer
- 11 **Survey**
 - Low Recognition Rate for AMD: Novartis Survey
 - Physicians Know Little about RLS: RLS Hotline

REGULATORY

- 12 Takeda Obtains Approval for Lansoprazole's Successor in US
 - Launching Expected within One Month
- 12 FDA Advisory Committee Recommends Approval of Prasugrel

- 13 Astellas Withdraws NDA for Controlled-Release Formulation of Tacrolimus in US
- 13 Strattera Recommended for Approval for AD/HD
- 15 Draft Guidance for Biosimilars Explained
 - Biosimilars Should Be Excluded from Comparator Products
- 15 PMDA to Take More PE-Based Post-Marketing Safety Measures
- 16 **REGULATORY NEWS IN BRIEF**
 - Council Recommends Health Insurance Coverage for KRAS Gene Mutation Tests
- 16 **TOPICS**
 - Astellas Has Strongest Image: NPhA Survey

R&D

- 17 Takeda Starts PI in Japan for DPP-4 Inhibitor + Actos Combination
- 17 NDAs Pending or Expected Soon for 3 Blockbuster Candidates: Novartis
- 17 **R&D NEWS IN BRIEF**
 - Pfizer Stops Global PIII Trial of Axitinib in Advanced Pancreatic Cancer
 - Oncolys Initiates PIB Study for Festinavir in HIV Infection in France
 - Active Development of Pancreatic Cancer Drugs Expected

SELF-MEDICATION

- 18 Ministerial Ordinance Issued Prohibiting Online Sale of Class 1, 2 OTC Drugs
 - Posting of Specific Information Required
 - Group Set Up to Discuss Online Sale of OTC Drugs
 - Pro-Online Sale Group Calls for Revision of Ordinance
- 19 **SELF-MEDICATION NEWS IN BRIEF**
 - Paltac's Healthcare Business Moves into the Black
 - Alfresa HD to Enhance Focuses on Foods and Health

MEDICAL DEVICES

- 20 BD Expands Portfolio for Uterocervical Cancer Cytodiagnosis System
- 20 **MEDICAL DEVICE NEWS IN BRIEF**
 - Alternative to Baxter's Bone Marrow Collection Kit Arrived at Narita
 - Medtronic Launches Attain Ability Lead for CRT Ahead of the US
 - Arkray Launches Desktop Device for Automatic SNPs Testing

MEDICAL FACILITIES & NURSING CARE

- 21 New GL Recommends Hp Eradication for All Hp-Related Diseases
 - JSHR Calls For Insurance Coverage for Hp Eradication
 - JSHR to Certify Hp Eradication Therapy Specialists
 - Hokkaido Univ. Hospital to Open Hp Clinic
- 22 **MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF**
 - Sanofi-aventis to Educate Consumers about Histamine-Induced Impaired Performance
 - Pharma. Association to Promote *Bungyo* Directly to Patients
 - JSHP Not Considering Merger with JPA: JSHP President
- 23 **Commentary**
 - National Consensus Needed to Balance Soaring Costs of New Drugs against Their Benefits